Sensei Biotherapeutics (NASDAQ:SNSE) Raised to “Hold” at Wall Street Zen

Sensei Biotherapeutics (NASDAQ:SNSE) was upgraded by Wall Street Zen to a “hold” rating in a report issued on Saturday.

Several other research analysts have also weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday. HC Wainwright lowered shares of Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Sensei Biotherapeutics Stock Down 2.8%

Shares of NASDAQ:SNSE opened at $9.00 on Friday. The company has a market cap of $11.34 million, a P/E ratio of -0.47 and a beta of 0.32. The business has a fifty day simple moving average of $9.13 and a 200-day simple moving average of $8.81. Sensei Biotherapeutics has a 52 week low of $5.00 and a 52 week high of $18.35.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its earnings results on Friday, November 14th. The company reported ($3.62) earnings per share for the quarter, topping the consensus estimate of ($4.11) by $0.49. Sell-side analysts expect that Sensei Biotherapeutics will post -1.17 earnings per share for the current fiscal year.

Insider Activity

In other news, major shareholder James Peyer sold 3,507 shares of the business’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $7.96, for a total transaction of $27,915.72. Following the completion of the sale, the insider owned 155,142 shares in the company, valued at approximately $1,234,930.32. The trade was a 2.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders sold 27,907 shares of company stock worth $287,280. 23.20% of the stock is currently owned by insiders.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.